Patents & Licensing
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.
Gilead’s early, systematic approach towards non-exclusive voluntary licensing helps efficient scale up and affordable supply of patented medicines in low- and middle-income countries.
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.